Shield Bio

Shield Bio is a biotechnology startup dedicated to fighting antibiotic resistance through innovative genomic testing. The company's slogan captures its mission succinctly, emphasizing the importance of managing treatable infections to stave off a potential health crisis. With a founding year of 2016, Shield Bio operates in the biotechnology and healthcare industries, addressing a pressing global healthcare issue. The alarming prediction that antibiotic-resistant pathogens could surpass cancer in mortality rates by 2050 underscores the urgency of Shield Bio's work. The company highlights the escalating challenges posed by antibiotic resistance, pointing out the shift from simple oral antibiotics to increasingly complex and painful treatments for once manageable infections. Shield Bio emphasizes the severe health implications for patients as a result of these developments, stressing the gravity of the situation. One example cited by Shield Bio is the concerning case of gonorrhea, which has developed resistance to over ten different antibiotics, leaving only one effective treatment, which is also showing signs of resistance. The rapidly spreading antibiotic resistance, with 820,000 new infections annually in the U.S., has prompted the CDC to classify resistant gonorrhea as an urgent threat, their highest alert level. Shield Bio's solution lies in its innovative genomic testing platform, which enables STI clinics to identify antibiotic-resistant strains of gonorrhea and other pathogens in their patients. This, in turn, allows for the selection of effective antibiotics, thus curbing the spread of antibiotic resistance. The startup's focus on providing practical, immediate solutions to a critical healthcare issue demonstrates its potential to make a significant impact on public health. The company's most recent milestone was the Pre Seed Round investment on 01 April 2019, signifying a vote of confidence from investors in Shield Bio's mission and technological approach. While the specific investor details are not available, this investment underscores the recognition of Shield Bio's potential to address a pressing global health issue. As Shield Bio continues to develop and deploy its innovative genomic testing platform, it stands poised to contribute meaningfully to the fight against antibiotic resistance and the preservation of effective treatments for infectious diseases.